UNSPSC 51373462: Dihydrocodeine/guaifenesin/pheniramine/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373462 Dihydrocodeine/guaifenesin/pheniramine/phenylephrine/phenylpropanolamine is a Commodity code that in practice captures state and local procurement of generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesale channels to health departments, community health facilities, and participating government agencies. The solicitations posted under this code show state and local buyers sourcing finished pharmaceutical products—including naloxone and drug deactivation systems, as well as broader generic pharmaceutical catalogs—for community health and emergency response programs. Issuing bodies include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances administering pharmaceutical contracts on behalf of participating state and local members (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, representing Minnesota, Oregon, and other jurisdictions). Vendors must meet FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and maintain contractual relationships with authorized wholesalers such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC.

The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a proposal deadline of March 26, 2026 and contract effectiveness of July 1, 2026; evaluation weighted pricing competitiveness at 75 percent and required vendors to certify cGMP and DSCSA compliance, maintain relationships with at least two of three authorized wholesalers with chargeback systems, and carry commercial general liability of $5 million per occurrence. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 for naloxone and drug deactivation systems—1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries—with a response deadline of July 26, 2023 and a two-year initial term plus optional one-year renewal. Both solicitations require vendors to submit detailed product information including National Drug Codes, maintain comprehensive insurance, and comply with federal regulations including the Clean Air Act and Federal Water Pollution Control Act when FEMA funding is involved.